Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 Current Ratio is 0.73 as of Jun. 2026, which is 1% below its 10-year median of 0.74. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Medpace Holdings ranks worse than 84.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Medpace Holdings's current ratio for the quarter that ended in Jun. 2026 was 0.73.
Medpace Holdings has a current ratio of 0.73. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Medpace Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Medpace Holdings's Current Ratio or its related term are showing as below:
FRA:01P'
s Current Ratio Range Over the Past 10 Years
Min: 0.37 Med: 0.74 Max: 1.24
Current: 0.73
During the past 13 years, Medpace Holdings's highest Current Ratio was 1.24. The lowest was 0.37. And the median was 0.74.
FRA:01P's Current Ratio is ranked worse than 84.04% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs FRA:01P: 0.73
Medpace Holdings (FRA:01P) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Medpace Holdings Current Ratio Related Terms
Medpace Holdings Current Ratio Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:01P vs ICLR, RVTY, CRL: Current Ratio Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (FRA:01P) has a Current Ratio of 0.73 as of Jun. 2026. This is near median its historical median of 0.74. Over the past decade, Medpace Holdings' Current Ratio has ranged from 0.37 to 1.24. According to the industry distribution chart, Medpace Holdings ranks #179 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 84%.
Is Medpace Holdings' Current Ratio too high?
Medpace Holdings' current Current Ratio of 0.73 is near median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 1.24. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Medpace Holdings' value of 0.73 is 65.2% below this industry median. Based on the distribution chart, Medpace Holdings ranks #179 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Current Ratio compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #179 out of 213 companies for Current Ratio. This places Medpace Holdings in the lower half of its industry. The industry median Current Ratio is 2.10. Medpace Holdings' value of 0.73 is 65.2% below this benchmark. Historically, Medpace Holdings' own Current Ratio has ranged from 0.37 to 1.24 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 2.10, Medpace Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Current Ratio of 0.73 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Current Ratio is 0.73, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Current Ratio is 0.73, which is near median its 10-year median of 0.74 and 65.2% below the Medical Diagnostics & Research industry median of 2.10. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Current Ratio is 0.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
Current Ratio: 0.73 (near median its 10-year median of 0.74)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
Industry Position: 65.2% below the Medical Diagnostics & Research median (#179 of 213)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
